

Göttingen, Germany | June 17, 2025

Sartorius expands manufacturing and R&D capacities for innovative bioprocess solutions in France

- Extended campus at headquarters of French sub-group Sartorius Stedim Biotech in Aubagne
- Significantly increased capacities for manufacturing, logistics, and R&D of single-use bags

The life science group Sartorius today celebrates the completion of a multi-year capacity expansion project at the headquarters of its French sub-group Sartorius Stedim Biotech in Aubagne. The investments highlight Sartorius' commitment to providing customers with innovative fluid management technologies.

"By investing in innovation, automation, and sustainability, we are strengthening our ability to meet the evolving needs of our customers while ensuring our competitive positioning and preparing for future growth," said René Fáber, Member of the Sartorius Executive Board and CEO of Sartorius Stedim Biotech.

Sartorius almost doubled cleanroom space in Aubagne, enhancing production lines for 2D and 3D single-use bags. Certified with ISCC Plus¹, the site uses renewable raw materials for plastic components. In addition, the company adopted ISO 14001 to enhance the environmental performance of its operations. An automated logistics facility accelerates raw material handling, and a cross-functional lab space fosters collaboration with customers. The campus received several sustainability and biodiversity certifications.

The Aubagne campus is part of Sartorius' global expansion of research and production capacities. These investments aim to prepare the company's infrastructure for further organic growth and to strengthen the flexibility and diversification of the production network - supporting consistent delivery reliability and product quality across all regions.

For more information, read the <u>full media release of Sartorius Stedim Biotech (English)</u>
Click here for <u>images of Sartorius Stedim Biotech Aubagne</u>

A profile of Sartorius

Sartorius is a leading international partner to life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. Based in Göttingen, Germany,

¹ International Sustainability and Carbon Certification PLUS (ISCC PLUS)

the company has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. More than 13,500 employees work for customers around the globe.

Visit our Newsroom or follow us on LinkedIn.

Contacts

Petra Kirchhoff Head of Corporate Communications & IR +49 551 308 1686 petra.kirchhoff@sartorius.com